medpagetoday.com
Apr 8, 2025, 08:03
George Vlachogiannis: A major driver of morbidity and poor outcomes in advanced NSCLC
George Vlachogiannis, Managing Editor at Cancer Control, shared a post on LinkedIn:
“A comprehensive clinicogenomic analysis of data from ~4,000 patients with lung adenocarcinoma (LUAD) obtained from the MSK MetTropism cohort identifies key clinical and genetic markers associated with bone metastases—a major driver of morbidity and poor outcomes in advanced NSCLC.
Key findings:
- Bone metastases were linked to specific co-metastases (e.g., liver, CNS) and mutations in TP53, EGFR, KEAP1, and MYC.
- Poor prognosis in bone metastatic LUAD was associated with age >75, female sex, EGFR wild-type status, and mutations in KEAP1, MYC, KRAS, and SMARCA4.
Observations can improve risk stratification and inform targeted monitoring strategies.”
Authors: Ahmed H. Al Sharie et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 13:00